Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
Lijing Wang
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 1547-1559
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Vivek P. Chavda, Jinal Ajabiya, Divya Teli, et al.
Molecules (2022) Vol. 27, Iss. 13, pp. 4315-4315
Open Access | Times Cited: 120
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 102
Natural products and drug discovery
David Newman
National Science Review (2022) Vol. 9, Iss. 11
Open Access | Times Cited: 73
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Philip N. Newsome, Phil Ambery
Journal of Hepatology (2023) Vol. 79, Iss. 6, pp. 1557-1565
Open Access | Times Cited: 67
Glucagon-Like Peptide-1: New Regulator in Lipid Metabolism
Tong Bu, Ziyan Sun, Yi Pan, et al.
Diabetes & Metabolism Journal (2024) Vol. 48, Iss. 3, pp. 354-372
Open Access | Times Cited: 19
The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
Thomas Leth Jensen, Andreas Brønden, Kristian Karstoft, et al.
Patient Preference and Adherence (2024) Vol. Volume 18, pp. 373-382
Open Access | Times Cited: 10
Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide
Fatemeh Taktaz, Rosaria Anna Fontanella, Lucia Scisciola, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 9
The signaling pathways in obesity‐related complications
Preethi Chandrasekaran, Ralf Weiskirchen
Journal of Cell Communication and Signaling (2024) Vol. 18, Iss. 2
Open Access | Times Cited: 8
Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
Binbin Gong, Zhihong Yao, Chenxu Zhou, et al.
European Journal of Medicinal Chemistry (2024) Vol. 269, pp. 116342-116342
Closed Access | Times Cited: 7
Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis
Qingyue Zeng, Jiao Xu, Xingyu Mu, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 17
Non-Insulin-Based Drug Entities Used to Treat Diabetes Type 2 Disease (T2DM), Based on Natural Products from All Sources
David Newman
Journal of Natural Products (2024) Vol. 87, Iss. 3, pp. 629-637
Closed Access | Times Cited: 6
Biased agonism in peptide-GPCRs: A structural perspective
Tharindunee Jayakody, Dinath Kavishka Budagoda, Krishan Mendis, et al.
Pharmacology & Therapeutics (2025), pp. 108806-108806
Open Access
Tirzepatide - a promising medication for cardiovascular protection and treatment of Type 2 diabetes and obesity
Pavlína Piťhová
Vnitřní lékařství (2025) Vol. 71, Iss. 1, pp. 51-57
Closed Access
Tirzepatide against obesity and insulin-resistance: pathophysiological aspects and clinical evidence
Salvatore Corrao, C Pollicino, Dalila Maggio, et al.
Frontiers in Endocrinology (2024) Vol. 15
Open Access | Times Cited: 4
Recent advances, strategies, and future perspectives of peptide-based drugs in clinical applications
Qimeng Yang, Zhipeng Hu, Hongyu Jiang, et al.
Chinese Journal of Natural Medicines (2025) Vol. 23, Iss. 1, pp. 31-42
Closed Access
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Wen‐Jing Xiao, Wenjie Jiang, Zheng Chen, et al.
Signal Transduction and Targeted Therapy (2025) Vol. 10, Iss. 1
Open Access
Post-marketing safety monitoring of Tirzepatide: a pharmacovigilance study based on the FAERS database
Han Chen, Y. Ding, Yongqi Shan
Expert Opinion on Drug Safety (2025)
Closed Access
Polypharmacology: new drugs in 2023–2024
Piotr Ryszkiewicz, Barbara Malinowska, Eberhard Schlicker
Pharmacological Reports (2025)
Open Access
The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 9
Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
Alexandros L. Liarakos, Chrysi Koliaki
Biomedicines (2023) Vol. 11, Iss. 7, pp. 1875-1875
Open Access | Times Cited: 7
Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide, and Glucagon Receptor Agonists in Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Medication in New Liver Disease Nomenclature
Lampros Chrysavgis, Spyridon Kazanas, Konstantina Bafa, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3832-3832
Open Access | Times Cited: 2
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Abhishek Kumar, Rupa Mazumder, Anjna Rani, et al.
Current Diabetes Reviews (2023) Vol. 20, Iss. 4
Closed Access | Times Cited: 2
Tirzepatide – a new analogue of incretin hormones
Gabriela Anglart, Laura Janik, Katarzyna Dettlaff
Farmacja Polska (2023) Vol. 79, Iss. 5, pp. 289-296
Open Access | Times Cited: 2
An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits
Xuan Xia, Qianmeng Lin, Zhan Zhou, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109377-109377
Open Access
Tirzepatide: unveiling a New Dawn in Dual-Targeted diabetes and obesity management
Syed Arman Rabbani, Mohamed El‐Tanani, Ismail Matalka, et al.
Expert Review of Endocrinology & Metabolism (2024) Vol. 19, Iss. 6, pp. 487-505
Closed Access
Page 1 - Next Page

Scroll to top